TABLE OF CONTENTS
1 INTRODUCTION 72
1.1 OBJECTIVES OF THE STUDY 72
1.2 MARKET DEFINITION 72
1.3 OVERVIEW OF THE GLOBAL RADIOPHARMACEUTICALS MARKET 72
1.4 LIMITATIONS 74
1.5 MARKETS COVERED 74
2 MARKET SEGMENTATION 77
2.1 MARKETS COVERED 77
2.2 GEOGRAPHICAL SCOPE 78
2.3 YEARS CONSIDERED FOR THE STUDY 79
2.4 CURRENCY AND PRICING 79
2.5 DBMR TRIPOD DATA VALIDATION MODEL 80
2.6 MULTIVARIATE MODELLING 83
2.7 PRODUCT TYPE LIFELINE CURVE 83
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 84
2.9 DBMR MARKET POSITION GRID 85
2.10 MARKET TESTING TYPE COVERAGE GRID 87
2.11 VENDOR SHARE ANALYSIS 88
2.12 SECONDARY SOURCES 89
2.13 ASSUMPTIONS 89
3 EXECUTIVE SUMMARY 90
4 PREMIUM INSIGHTS 93
4.1 PESTEL ANALYSIS 96
4.2 PORTERS FIVE FORCES 97
4.3 PIPELINE ANALYSIS 98
4.4 PATENT ANALYSIS 99
4.5 DRUG TREATMENT RATE BY MATURED MARKETS 105
4.6 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES 106
4.7 PATIENT FLOW DIAGRAM 107
4.8 KEY PRICING STRATEGIES 107
4.9 KEY PATIENT ENROLLMENT STRATEGIES 108
5 LIST OF CYCLOTRONS 110
5.1 NORTH AMERICA 110
5.2 EUROPE 117
6 REGULATORY SCENARIO 129
6.1 NORTH AMERICA 129
6.2 EUROPE 129
6.3 ASIA-PACIFIC 130
6.4 MIDDLE EAST AND AFRICA 131
7 MARKET OVERVIEW 132
7.1 DRIVERS 134
7.1.1 THE GROWING DEMAND FOR RADIOPHARMACEUTICALS IN DIAGNOSTICS AND CLINICAL USE 134
7.1.2 THE INCREASING NEED FOR PHARMACEUTICAL PRODUCTS ACROSS VARIED THERAPEUTIC AREAS 134
7.1.3 THE INCREASING PREVALENCE OF CHRONIC DISEASES 135
7.2 RESTRAINTS 135
7.2.1 STRINGENT REGULATIONS FOR RADIOPHARMACEUTICALS 135
7.2.2 POTENTIAL RISKS ASSOCIATED WITH RADIOPHARMACEUTICALS 135
7.3 OPPORTUNITIES 136
7.3.1 THE RISING RESEARCH AND DEVELOPMENT EXPENDITURE OF RADIOPHARMACEUTICALS 136
7.3.2 THE GROWING INCIDENCES OF COMPLEX DISEASES IN GERIATRIC POPULATION 136
7.4 CHALLENGES 137
7.4.1 HIGH COST OF DEVELOPMENT AND IMPLEMENTATION OF RADIOPHARMACEUTICALS 137
7.4.2 LACK OF TECHNICAL EXPERTISE AND HIGH COST FOR TRAINING EXISTING WORKFORCE 138
8 GLOBAL RADIOPHARMACEUTICALS MARKET, BY TYPE 139
8.1 OVERVIEW 140
8.2 DIAGNOSTIC RADIOPHARMACEUTICALS 143
8.2.1 PET RADIOPHARMACEUTICALS 144
8.2.1.1 F-18 144
8.2.1.2 RU-82 144
8.2.1.3 OTHER PET ISOTOPES RADIOPHARMACEUTICALS 144
8.2.2 SPECT RADIOPHARMACEUTICALS 145
8.2.2.1 TECHNETIUM-99M 145
8.2.2.2 GALLIUM-67 145
8.2.2.3 IODINE-123 145
8.2.2.4 THALLIUM-201 145
8.2.2.5 OTHER SPECT ISOTOPES 145
8.3 THERAPEUTIC RADIOPHARMACEUTICALS 146
8.3.1 BRACHYTHERAPY ISOTOPES 147
8.3.1.1 IODINE-125 147
8.3.1.2 PALLADIUM-103 147
8.3.1.3 CESIUM-131 147
8.3.1.4 IRIDIUM-192 148
8.3.1.5 OTHER BRACHYTHERAPY ISOTOPES 148
8.3.2 BETA EMITTERS 148
8.3.2.1 IODINE-131 148
8.3.2.2 LUTHETIUM-177 148
8.3.2.3 SAMARIUM-153 148
8.3.2.4 YTTRIUM-90 148
8.3.2.5 RHENIUM-186 149
8.3.2.6 OTHER BETA EMITTERS 149
8.3.3 ALPHA EMITTERS 149
8.3.3.1 RA-223 149
8.3.3.2 OTHERS 149
9 GLOBAL RADIOPHARMACEUTICALS MARKET, BY APPLICATION 150
9.1 OVERVIEW 151
9.2 DIAGNOSTIC 154
9.2.1 PET 155
9.2.1.1 ONCOLOGY 155
9.2.1.2 CARDIOLOGY 155
9.2.1.3 NEUROLOGY 155
9.2.1.4 OTHER PET APPLICATION 155
9.2.2 SPECT 156
9.2.2.1 CARDIOLOGY 156
9.2.2.2 BONE SCANS 156
9.2.2.3 THYROID APPLICATIONS 156
9.2.2.4 PULMONARY SCANS 156
9.2.2.5 OTHER SPECT APPLICATION 156
9.3 THERAPEUTIC 157
9.3.1 THYROID INDICATIONS 158
9.3.2 BONE METASTASIS 158
9.3.3 LYMPHOMA 158
9.3.4 ENDOCRINE TUMORS 158
9.3.5 OTHER INDICATIONS 158
10 GLOBAL RADIOPHARMACEUTICALS MARKET, BY SOURCE 159
10.1 OVERVIEW 160
10.2 NUCLEAR REACTORS 163
10.3 CYCLOTRONS 164
11 GLOBAL RADIOPHARMACEUTICALS MARKET, BY END USER 165
11.1 OVERVIEW 166
11.2 HOSPITALS 169
11.3 DIAGNOSTIC CENTERS 169
11.4 CANCER RESEARCH INSTITUTES 170
11.5 AMBULATORY SURGICAL CENTERS 171
11.6 OTHERS 172
12 GLOBAL RADIOPHARMACEUTICALS MARKET, BY REGION 173
12.1 OVERVIEW 174
12.2 NORTH AMERICA 179
12.2.1 U.S. 193
12.2.2 CANADA 202
12.2.3 MEXICO 211
12.3 EUROPE 220
12.3.1 GERMANY 231
12.3.2 U.K. 238
12.3.3 FRANCE 245
12.3.4 ITALY 252
12.3.5 SPAIN 259
12.3.6 BELGIUM 266
12.3.7 POLAND 273
12.3.8 RUSSIA 280
12.3.9 NORWAY 287
12.3.10 TURKEY 294
12.3.11 AUSTRIA 300
12.3.12 IRELAND 307
12.3.13 HUNGARY 314
12.3.14 NETHERLANDS 321
12.3.15 SWITZERLAND 328
12.3.16 REST OF EUROPE 335
12.4 ASIA PACIFIC 336
12.4.1 CHINA 347
12.4.2 AUSTRALIA 354
12.4.3 JAPAN 361
12.4.4 SOUTH KOREA 368
12.4.5 SINGAPORE 375
12.4.6 INDIA 382
12.4.7 INDONESIA 389
12.4.8 PHILIPPINES 396
12.4.9 THAILAND 403
12.4.10 MALAYSIA 410
12.4.11 VIETNAM 417
12.4.12 REST OF ASIA-PACIFIC 424
12.5 MIDDLE EAST AND AFRICA 425
12.5.1 SOUTH AFRICA 436
12.5.2 EGYPT 443
12.5.3 SAUDI ARABIA 449
12.5.4 U.A.E. 456
12.5.5 KUWAIT 463
12.5.6 ISRAEL 470
12.5.7 REST OF MIDDLE EAST AND AFRICA 477
12.6 SOUTH AMERICA 478
12.6.1 BRAZIL 489
12.6.2 ARGENTINA 496
12.6.3 CHILE 503
12.6.4 COLOMBIA 510
12.6.5 PERU 517
12.6.6 VENEZUELA 524
12.6.7 ECUADOR 531
12.6.8 REST OF SOUTH AMERICA 537
13 GLOBAL RADIOPHARMACEUTICALS MARKET: COMPANY LANDSCAPE 538
13.1 COMPANY SHARE ANALYSIS: GLOBAL 538
13.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 539
13.3 COMPANY SHARE ANALYSIS: EUROPE 540
13.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 541
14 SWOT ANALYSIS 542
15 COMPANY PROFILE 543
15.1 CARDINAL HEALTH 543
15.1.1 COMPANY SNAPSHOT 543
15.1.2 REVENUE ANALYSIS 543
15.1.3 COMPANY SHARE ANALYSIS 544
15.1.4 PRODUCT PORTFOLIO 544
15.1.5 RECENT DEVELOPMENT 545
15.2 ADVANCED ACCELERATOR APPLICATIONS, A NOVARTIS COMPANY 546
15.2.1 COMPANY SNAPSHOT 546
15.2.2 REVENUE ANALYSIS 546
15.2.3 COMPANY SHARE ANALYSIS 547
15.2.4 PRODUCT PORTFOLIO 547
15.2.5 RECENT DEVELOPMENT 547
15.3 LANTHEUS 548
15.3.1 COMPANY SNAPSHOT 548
15.3.2 REVENUE ANALYSIS 548
15.3.3 COMPANY SHARE ANALYSIS 549
15.3.4 PRODUCT PORTFOLIO 549
15.3.5 RECENT DEVELOPMENT 549
15.4 CURIUM 550
15.4.1 COMPANY SNAPSHOT 550
15.4.2 COMPANY SHARE ANALYSIS 550
15.4.3 PRODUCT PORTFOLIO 551
15.4.4 RECENT DEVELOPMENT 551
15.5 GENERAL ELECTRIC COMPANY 552
15.5.1 COMPANY SNAPSHOT 552
15.5.2 REVENUE ANALYSIS 552
15.5.3 COMPANY SHARE ANALYSIS 553
15.5.4 PRODUCT PORTFOLIO 553
15.5.5 RECENT DEVELOPMENT 553
15.6 BRACCO 554
15.6.1 COMPANY SNAPSHOT 554
15.6.2 PRODUCT PORTFOLIO 554
15.6.3 RECENT DEVELOPMENT 554
15.7 BWX TECHNOLOGIES. INC. 555
15.7.1 COMPANY SNAPSHOT 555
15.7.2 REVENUE ANALYSIS 555
15.7.3 PRODUCT PORTFOLIO 556
15.7.4 RECENT DEVELOPMENT 556
15.8 CHINA ISOTOPE & RADIATION CORPORATION 557
15.8.1 COMPANY SNAPSHOT 557
15.8.2 REVENUE ANALYSIS 557
15.8.3 PRODUCT PORTFOLIO 558
15.8.4 RECENT DEVELOPMENT 558
15.9 COQUI RADIOPHARMACEUTICALS CORP. 559
15.9.1 COMPANY SNAPSHOT 559
15.9.2 PRODUCT PORTFOLIO 559
15.9.3 RECENT DEVELOPMENT 559
15.10 ECKERT & ZIEGLER 560
15.10.1 COMPANY SNAPSHOT 560
15.10.2 REVENUE ANALYSIS 560
15.10.3 PRODUCT PORTFOLIO 561
15.10.4 RECENT DEVELOPMENT 561
15.11 ECZACIBAI-MONROL 562
15.11.1 COMPANY SNAPSHOT 562
15.11.2 PRODUCT PORTFOLIO 562
15.11.3 RECENT DEVELOPMENT 562
15.12 EVERGREEN THERAGNOSTICS, INC. 563
15.12.1 COMPANY SNAPSHOT 563
15.12.2 PRODUCT PORTFOLIO 563
15.12.3 RECENT DEVELOPMENT 563
15.13 GLOBAL MEDICAL SOLUTIONS 564
15.13.1 COMPANY SNAPSHOT 564
15.13.2 PRODUCT PORTFOLIO 564
15.13.3 RECENT DEVELOPMENT 564
15.14 IBA WORLDWIDE 565
15.14.1 COMPANY SNAPSHOT 565
15.14.2 REVENUE ANALYSIS 565
15.14.3 PRODUCT PORTFOLIO 566
15.14.4 RECENT DEVELOPMENT 566
15.15 INSTITUTE OF ISOTOPES 567
15.15.1 COMPANY SNAPSHOT 567
15.15.2 PRODUCT PORTFOLIO 567
15.15.3 RECENT DEVELOPMENT 567
15.16 ISOTOPE JSC 568
15.16.1 COMPANY SNAPSHOT 568
15.16.2 PRODUCT PORTFOLIO 568
15.16.3 RECENT DEVELOPMENT 568

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.